Results 101 to 110 of about 527,379 (343)

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Different colony-stimulating factors are detected by the "interleukin- 3"-dependent cell lines FDC-Pl and 32D cl-23 [PDF]

, 1984
AJ Hapel, HS Warren, David Hume
openalex   +3 more sources

The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis

Frontiers in Immunology, 2018
Research into the pathophysiology of psoriasis has shed light onto many fascinating immunological interactions and underlying genetic constellations. Most prominent among these is the crosstalk between components of the innate and the adaptive immune ...
Michael P. Schön, Michael P. Schön, Luise Erpenbeck   +2 more
doaj   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Accelerated wound healing phenotype in Interleukin 12/23 deficient mice

Journal of Inflammation, 2011
Background The concept that a strong inflammatory response involving the full complement of cytokines and other mediators is critical for unimpaired healing has been challenged by wound healing studies using transgenic and knockout (KO) mice. The present
Matias Marie AT, Saunus Jodi M, Ivanovski Saso, Walsh Laurence J, Farah Camile S   +4 more
doaj   +1 more source

Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis [PDF]

, 2017
Background: Dysbiosis has been recently demonstrated in patients with ankylosing spondylitis (AS) but its implications in the modulation of intestinal immune responses have never been studied.
Alessandro, Riccardo, Ciccia, Francesco, Cypers, Heleen, Di Benedetto, Paola, Elewaut, Dirk, Fasano, Alessio, Gabrielli, Armando, Guggino, Giuliana, Luchetti, Michele Maria, Milling, Simon, Rizzo, Aroldo, Saieva, Laura, Stampone, Tommaso, Triolo, Giovanni   +13 more
core   +2 more sources

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer

Iranian Journal of Medical Sciences, 2014
Background: Interleukin (IL)-23 and IL-27 are two IL-12-related cytokines which their function may dramatically influence the inflammatory response to tumor development. IL-12 and IL-27 seem to have antagonistic roles with IL-23 in tumor site.
Ali Khodadadi, Mahboobeh Razmkhah, Ali-Reza Eskandari, Ahmad Hosseini, Mojtaba Habibagahi, bbas Ghaderi, Mansooreh Jaberipour   +6 more
doaj  

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Actas Dermo-Sifiliográficas
Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response.
R. Rivera-Díaz, A. Quesada, A. Sahuquillo-Torralba, E. Daudén, J.M. Carrascosa, I. Belinchón, F.J. Gomez Garcia, E. Herrera Acosta, D.P. Ruiz Genao, O. Baniandrés Rodriguez, M. Ferrán Farres, P. de la Cueva Dobao, L.R. Fernández-Freire, A. Mateu Puchades, J. Riera-Monroig, J.C. Ruiz Carrascosa, M. Ara Martín, M. Abalde Pintos, M. Roncero Riesco, J.L. Lopez-Estebaranz, C. García-Donoso, I. García-Doval, M. Angel Descalzo   +22 more
doaj   +1 more source

Therapeutic Mode of Action of Methotrexate

Central Asian Journal of Medical Sciences, 2016
Objectives: Methotrexate (MTX) has been used in clinical practice for over a half-century and its action mechanism is believed to rely on the direct inhibition of DNA synthesis leading to suppression of cell proliferation.
Dashlkhumbe Byamba, Do-Young Kim, Chimidtseren Soodoi, Enkhtur Yadamsuren, Ariunaa Munkhbayar, Nandintsetseg Batbayar, Dashkhajidmaa Dashdondov, Oyuntsatsral Batsaikhan, Batbaatar Gunchin, Min-Geol Lee   +9 more
doaj   +1 more source